

BIO REFERENCE LABORATORIES INC
Form SC 13G/A
February 13, 2014

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Bio-Reference Laboratories, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

09057G602

(CUSIP Number)

December 31, 2013

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

XRule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 09057G602

NAME OF REPORTING PERSON

1

Manulife Financial Corporation
CHECK THE APPROPRIATE BOX IF A MEMBER OF A
GROUP* (a) £

2

(b) £

N/A
SEC USE ONLY

3

CITIZENSHIP OR PLACE OF ORGANIZATION

4

Canada
SOLE VOTING POWER

5

Number of
Shares

-0-
SHARED VOTING POWER

Beneficially

6

Owned by
Each

-0-
SOLE DISPOSITIVE POWER

7

Reporting
Person

-0-
SHARED DISPOSITIVE POWER

8

With

-0-

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9

None, except through its indirect, wholly-owned subsidiaries, Manulife Asset Management (US) LLC, Manulife Asset Management (North America) Limited and Manulife Asset Management Limited

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

10

N/A

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

11

See line 9 above.

TYPE OF REPORTING PERSON*

12

HC

***SEE INSTRUCTIONS**

CUSIP No. 09057G602

NAME OF REPORTING PERSON

1

Manulife Asset Management (US) LLC
CHECK THE APPROPRIATE BOX IF A MEMBER OF A
GROUP* (a) £

2

(b) £

N/A
SEC USE ONLY

3

CITIZENSHIP OR PLACE OF ORGANIZATION

4

Delaware
SOLE VOTING POWER

5

Number of 11,302
Shares SHARED VOTING POWER

Beneficially 6

Owned by -0-
SOLE DISPOSITIVE POWER

Each 7

Reporting 11,302
Person SHARED DISPOSITIVE POWER

With 8

-0-
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9

11,302
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

N/A

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

11

0.04%

TYPE OF REPORTING PERSON*

12

IA

***SEE INSTRUCTIONS**

CUSIP No. 09057G602

NAME OF REPORTING PERSON

1

Manulife Asset Management (North America) Limited
CHECK THE APPROPRIATE BOX IF A MEMBER OF A
GROUP* (a) £

2

(b) £

N/A
SEC USE ONLY

3

CITIZENSHIP OR PLACE OF ORGANIZATION

4

Canada
SOLE VOTING POWER

5

Number of 7,468
Shares SHARED VOTING POWER

Beneficially 6

Owned by -0-
SOLE DISPOSITIVE POWER

Each 7

Reporting 7,468
Person SHARED DISPOSITIVE POWER

With 8

-0-

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9

7,468

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

N/A

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

11

0.03%

TYPE OF REPORTING PERSON*

12

IA

***SEE INSTRUCTIONS**

CUSIP No. 09057G602

NAME OF REPORTING PERSON

1

Manulife Asset Management Limited
CHECK THE APPROPRIATE BOX IF A MEMBER OF A
GROUP* (a) £

2

(b) £

N/A
SEC USE ONLY

3

CITIZENSHIP OR PLACE OF ORGANIZATION

4

Ontario
SOLE VOTING POWER

5

Number of 1,381,385
Shares SHARED VOTING POWER

6

Beneficially -0-
Owned by SOLE DISPOSITIVE POWER

7

Each Reporting 1,381,385
SHARED DISPOSITIVE POWER

8

With -0-
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9

1,381,385

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

N/A

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

11

4.99%

TYPE OF REPORTING PERSON*

12

FI

***SEE INSTRUCTIONS**

CUSIP No. 09057G602

Item Name of Issuer:

1(a) Bio-Reference Laboratories, Inc.

Item Address of Issuer's Principal Executive Offices:

1(b) 481 Edward H. Ross Drive
Elmwood Park, New Jersey 07407-3118

Item Name of Person Filing:

2(a) This filing is made on behalf of Manulife Financial Corporation ("MFC") and MFC's indirect, wholly-owned subsidiaries, Manulife Asset Management (US) LLC ("MAM (US)"), Manulife Asset Management (North America) Limited ("MAM (NA)") and Manulife Asset Management Limited ("MAML").

Item Address of Principal Business Office:

2(b) The principal business offices of MFC, MAM (NA), MAML are located at 200 Bloor Street East, Toronto, Ontario, Canada, M4W 1E5.
The principal business office of MAM (US) is located at 197 Clarendon Street, Boston, Massachusetts 02116.

Item Citizenship:

2(c) MFC and MAM (NA) are organized and exist under the laws of Canada.
MAM (US) is organized and exists under the laws of the State of Delaware.
MAML is organized and exists under the laws of Ontario.

Item Title of Class of Securities:

2(d) Common Stock

Item CUSIP Number:

2(e) 09057G602

Item 3 If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

MFC: (g) a parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).

MAM (US): (e) an investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

MAM (NA): (e) an investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

MAML: (j) a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).

Item 4 Ownership:

(a) Amount Beneficially Owned: MAM (US) has beneficial ownership of 11,302 shares of Common Stock, MAM (NA) has beneficial ownership of 7,468 shares of Common Stock and MAML has beneficial ownership of 1,381,385 shares of Common Stock. Through its parent-subsidary relationship to MAM (US), MAM (NA) and MAML, MFC may be deemed to have beneficial ownership of these same shares.

(b) Percent of Class: Of the 27,695,213 shares outstanding as of January 4, 2014, according to the issuer's Annual Report filed on Form 10-K for the fiscal year ended October 31, 2013, MAM (US) held 0.04%, MAM (NA) held 0.03% and MAML held 4.99%.

(c) Number of shares as to which the person has:

- (i) sole power to vote or to direct the vote:
MAM (US), MAM (NA) and MAML each has sole power to vote or to direct the voting of the shares of Common Stock beneficially owned by each of them.
- (ii) shared power to vote or to direct the vote: -0-
- (iii) sole power to dispose or to direct the disposition of:
MAM (US), MAM (NA) and MAML each has sole power to dispose or to direct the disposition of the shares of Common Stock beneficially owned by each of them.
- (iv) shared power to dispose or to direct the disposition of: -0-

Item 5 Ownership of Five Percent or Less of a Class:

Not applicable.

Item 6 Ownership of More than Five Percent on Behalf of Another Person:

Not applicable.

Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

See Items 3 and 4 above.

Item 8 Identification and Classification of Members of the Group:

Not applicable.

Item 9 Notice of Dissolution of Group:

Not applicable.

Item 10 Certification:

By signing below the undersigned certifies that, to the best of its knowledge and belief, (i) the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, and (ii) the foreign regulatory scheme applicable to MAML, is substantially comparable to

the regulatory scheme applicable to the functionally equivalent U.S. institution. The undersigned also undertakes to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Manulife Financial Corporation

By: /s/ Kenneth G. Pogrinn

Name: Kenneth G. Pogrinn

Dated: February 11, 2014 Title: Attorney in Fact*

Manulife Asset Management (US) LLC

By: /s/ William E. Corson

Name: William E. Corson

Dated: February 11, 2014 Title: Vice President and Chief Compliance Officer

**Manulife Asset Management (North America)
Limited**

By: /s/ Kenneth G. Pogrinn

Name: Kenneth G. Pogrinn

Dated: February 11, 2014 Title: General Counsel and Secretary

Manulife Asset Management Limited

By: /s/ Kenneth G. Pogrinn

Name: Kenneth G. Pogrinn

Dated: February 11, 2014 Title: Vice President, Law

* Signed pursuant to a Power of Attorney dated January 17, 2008 included as an Exhibit to Schedule 13G filed with the Securities and Exchange Commission by Manulife Financial Corporation on January 24, 2008.

EXHIBIT A

JOINT FILING AGREEMENT

Manulife Financial Corporation, Manulife Asset Management (US) LLC, Manulife Asset Management (North America) Limited, and Manulife Asset Management Limited agree that the Schedule 13G (Amendment No. 1) to which this Agreement is attached, relating to the Common Stock of Bio-Reference Laboratories, Inc., is filed on behalf of each of them.

Manulife Financial Corporation

By: /s/ Kenneth G. Pogrinn

Name: Kenneth G. Pogrinn

Dated: February 11, 2014 Title: Attorney in Fact*

Manulife Asset Management (US) LLC

By: /s/ William E. Corson

Name: William E. Corson

Dated: February 11, 2014 Title: Vice President and Chief Compliance Officer

**Manulife Asset Management (North America)
Limited**

By: /s/ Kenneth G. Pogrinn

Name: Kenneth G. Pogrinn

Dated: February 11, 2014 Title: General Counsel and Secretary

Manulife Asset Management Limited

By: /s/ Kenneth G. Pogrinn

Name: Kenneth G. Pogrinn

Dated: February 11, 2014 Title: Vice President, Law

* Signed pursuant to a Power of Attorney dated January 17, 2008 included as an Exhibit to Schedule 13G filed with the Securities and Exchange Commission by Manulife Financial Corporation on January 24, 2008.